Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xarelto rivaroxaban: Phase III data

In the double-blind Phase III RECORD2 trial in 2,509 patients, rivaroxaban reduced

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE